The anti-PD-1-IL-15m (PF-07209960) was designed to deliver PD-1-mediated and avidity-driven IL-2/15 receptor stimulation to PD-1 positive tumor-infiltrating lymphocytes while minimally affecting circulating peripheral NK and T cells. The gene discussed is IL2; the disease is neoplasm.